Regeneron Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Regeneron Pharmaceuticals generated cash of $4,594,000,000, which is less than the previous year. Cash used in financing activities reached the amount of -$1,790,100,000 last year. Net change in cash is therefore -$381,600,000.
Cash Flow
| 2014 | 752.43M | -420.77M | -209.26M |
|---|---|---|---|
| 2015 | 1.33B | -907.60M | -262.79M |
| 2016 | 1.48B | -1.04B | -700.39M |
| 2017 | 1.30B | -1.00B | -24.4M |
| 2018 | 2.19B | -1.46B | -77.1M |
| 2019 | 2.43B | -2.02B | -252.1M |
| 2020 | 2.61B | -70.6M | -1.97B |
| 2021 | 7.08B | -5.38B | -1.00B |
| 2022 | 5.01B | -3.78B | -1.00B |
| 2023 | 4.59B | -3.18B | -1.79B |
REGN Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 3.11B | 2.89B | 2.20B | 1.63B | 1.48B | 825.2M | 535.20M | 809.10M | 648.71M | 535.60M |
Operating activities | ||||||||||
Net income | 3.95B | 4.33B | 8.07B | 3.51B | 2.11B | 2.44B | 1.19B | 895.52M | 636.05M | 348.07M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 421M | 341.4M | 286.2M | 235.9M | 210.3M | 148.2M | 145.46M | 104.74M | 74.90M | 52.68M |
Stock-based compensation expense | 885M | 725M | 601.7M | 432M | 464.3M | 0 | 507.27M | 559.87M | 459.04M | 307.23M |
| Deferred income tax benefit | 885M | 725M | 601.7M | 432M | 464.3M | 0 | 507.27M | 559.87M | 459.04M | 307.23M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -338.8M | 707.8M | -1.92B | -1.35B | -473.1M | -268.9M | -362.72M | -143.82M | -491.42M | -62.43M |
Inventories | -271.7M | -696.5M | -494.3M | -529.4M | -335.5M | -387.9M | -314.19M | -149.77M | -111.82M | -60.9M |
Accounts payable | 598.6M | -138.4M | 866.1M | 118.9M | 444.5M | 210M | -23.18M | 253.98M | 303.65M | 162.23M |
Cash generated by operating activities | 4.59B | 5.01B | 7.08B | 2.61B | 2.43B | 2.19B | 1.30B | 1.48B | 1.33B | 752.43M |
Investing activities | ||||||||||
Purchases Of Investments | -11.64B | -7.48B | -7.04B | -3.24B | -3.20B | -1.84B | -1.27B | -809.41M | -557.10M | -564.18M |
Investments In Property Plant And Equipment | 0 | -590.1M | -551.9M | -614.6M | -429.6M | -383.1M | -272.6M | -511.9M | -677.93M | -333.00M |
Acquisitions Net | -54.9M | -230.3M | 551.9M | 614.6M | 429.6M | 1.06B | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -3.18B | -3.78B | -5.38B | -70.6M | -2.02B | -1.46B | -1.00B | -1.04B | -907.60M | -420.77M |
Financing activities | ||||||||||
Common Stock Issued | 1.14B | 1.51B | 1.67B | 2.57B | 211.8M | 114.5M | 240.21M | 126.73M | 206.35M | 126.04M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -2.93B | -2.52B | -2.67B | -6.52B | -463.9M | -191.6M | -301.7M | -143.18M | -160.53M | -267.58M |
Repayments of term debt | 0 | 0 | 0 | -1.5B | 0 | 0 | 37.1M | -40.58M | -140.44M | -221.73M |
Cash used in financing activities | -1.79B | -1.00B | -1.00B | -1.97B | -252.1M | -77.1M | -24.4M | -700.39M | -262.79M | -209.26M |
Net Change In Cash | -381.6M | 221.3M | 690.8M | 577M | 150.1M | 655M | 277.53M | -273.89M | 160.38M | 113.11M |
Cash at end of period | 2.73B | 3.11B | 2.89B | 2.20B | 1.63B | 1.48B | 812.73M | 535.20M | 809.10M | 648.71M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |